1. MedTech vertical scale-up - MedTech annualized revenue is on track to cross ₹1,000 crore in FY27, roughly 15% of total revenue, with EBITDA margins of 4.5-4.75% post-integration versus 4% in Q2 FY26. MedTech carries higher gross and EBITDA margins than core pharma distribution, so this mix shift alone supports the 5% EBITDA margin floor and the path toward the 6% internal aspiration.
2. FY26 acquisition calendarization - The 7 acquisitions closed in FY26, including 3 in MedTech, contribute \~11-12% of the FY27 revenue growth guidance of 23% through calendarization alone, with no new deals needed. These deals were struck at single-digit EV/EBITDA multiples and are pro forma EBITDA margin accretive by 50-75 bps, so the growth is both funded and margin-enhancing.
3. Margin expansion programme - EBITDA margin hit 5% in Q1 FY27, hitting the full-year guidance in the first quarter, with gross margin up 147 bps YoY to 11.4%. Management calls 5% the floor and targets higher margins quarter-on-quarter, driven by scale-led procurement economies and the shift toward commercial-role MedTech engagements.
4. GLP-1 distribution share - Entero sells ₹10-12 crore of GLP-1 drugs per month, roughly 10% of the market, with cold chain facilities in all warehouses supporting disproportionate share. The market is expected to grow nearly fivefold to ₹4,500-5,000 crore by 2030, and new generic semaglutide entrants from March 2026 will expand the distributable base.
5. Organic growth outperformance - Organic revenue grew 17.8% in Q1 FY27, ahead of the 13.8% IPM growth, driven by wallet share gains and customer additions. Management targets 1.5-2x IPM growth and expects 20% combined growth over 3-4 years even without acquisitions, which at that pace would push ROCE to 25-30%.
6. Working capital release - Net working capital days improved to 61 in Q1 FY27 from 66 a year ago, and most working capital for FY27 is already in place. Incremental working capital needs are minimal unless growth exceeds 23%, so the FY27 EBITDA-to-operating-cash-flow conversion target of 50% is achievable without fresh funding.
7. Anand Chemiceutics integration - The 51.51% stake in Anand Chemiceutics closed February 7, 2026, adding a pan-India diagnostic distributor with 1,500+ laboratory and hospital customers and mid-double-digit gross margins. This single deal pushes MedTech past the ₹1,000 crore annualized revenue mark and brings EBITDA margins upwards of 10% into the consolidated mix.
8. Market consolidation tailwind - Large/national distributors' share of the US$33 billion Indian pharma distribution market is projected to rise from 8-10% in FY23 to 20-30% by FY28, a 25-30% CAGR. Entero is among the top three distributors nationally, with 135 warehouses across 523 districts, positioning it to capture this shift as 90% of the market remains unorganized.